Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

Table 6 Univariate and multivariate Cox analysis of prognostic factors in microsatellite stable metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy, n (%)

Dependent: Survival (PFS/30, status)		All	HR (univariable)	HR (multivariable)
Age	> 60	10 (35.7)	-	-
	≤ 60	18 (64.3)	1.47 (0.52-4.15, P = 0.466)	-
Gender	Male	15 (53.6)	-	-
	Female	13 (46.4)	1.34 (0.52-3.41, P = 0.543)	-
Location	Right colon	15 (53.6)	-	-
	Left colon and rectum	13 (46.4)	4.02 (1.38-11.70, P = 0.011)	1.34 (0.25-7.36, P = 0.733)
Number of metastatic organs	1	22 (78.6)	-	-
	≥ 2	6 (21.4)	0.90 (0.26-3.14, P = 0.870)	-
Liver metastasis	No	10 (35.7)	-	-
	Yes	18 (64.3)	0.73 (0.27-1.99, P = 0.540)	-
Lung metastasis	No	21 (75.0)	-	-
	Yes	7 (25.0)	1.20 (0.42-3.42, P = 0.727)	-
RAS	Unknown	8 (28.6)	-	-
	Wild type	5 (17.9)	1.61 (0.34-7.57, P = 0.544)	-
	Mutation	15 (53.6)	1.52 (0.42-5.52, P = 0.524)	-
CEA	1	10 (35.7)	-	-
	2	18 (64.3)	2.11 (0.74-6.01, P = 0.161)	-
CA199	1	19 (67.9)	-	-
	2	9 (32.1)	3.70 (1.27-10.77, P = 0.016)	2.56 (0.43-15.18, P = 0.301)
NLR	≤ 3.96	23 (82.1)	-	-
	> 3.96	5 (17.9)	4.72 (1.24-17.88, P = 0.023)	1.79 (0.19-17.36, P = 0.614)
LMR	≤ 6.45	25 (89.3)	-	-
	> 6.45	3 (10.7)	2.44 (0.67-8.84, P = 0.174)	-
BMI	≤ 18.73	3 (10.7)	-	-
	> 18.73	25 (89.3)	4.38 (0.56-34.10, P = 0.159)	-
ALI	≤ 205.20	9 (32.1)	-	-
	> 205.20	19 (67.9)	0.37 (0.14-1.00, P = 0.049)	0.33 (0.14-13.15, P = 0.805)
SII	≤ 926.18	21 (75.0)	-	-
	> 926.18	7 (25.0)	3.11 (1.10-8.81, P = 0.033)	2.54 (0.32-20.29, P = 0.379)
ALLC	≤ 4.85	8 (28.6)	-	-
	> 4.85	20 (71.4)	3.51 (1.12-11.04, P = 0.032)	11.52 (0.52-256.63, P = 0.123)
ANC	≤ 3.13	13 (46.4)	-	-
	> 3.13	15 (53.6)	2.56 (0.95-6.89, P = 0.064)	0.51 (0.07-3.53, P = 0.493)
ALC	≤ 1.15	7 (25.0)	-	-
	> 1.15	21 (75.0)	1.87 (0.53-6.60, P = 0.332)	-
AMC	≤ 0.32	7 (25.0)	-	-
	> 0.32	21 (75.0)	3.38 (0.96-11.90, P = 0.058)	1.30 (0.15-11.13, P = 0.814)
AEC	≤ 0.15	16 (57.1)	-	-
	> 0.15	12 (42.9)	2.52 (0.98-6.46, P = 0.055)	0.54 (0.10-3.07, P = 0.488)
RDW	≤ 13	6 (21.4)	-	-
	> 13	22 (78.6)	0.23 (0.07-0.76, P = 0.016)	0.26 (0.04-1.51, P = 0.133)
LDH	≤ 199	13 (46.4)	-	-
	> 199	15 (53.6)	3.44 (1.24-9.54, P =0 .018)	4.11 (1.02-16.55, P = 0.046)

PFS: Progression-free survival; HR: Hazard ratio; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; BMI: Body mass index; ALI: Advanced lung cancer inflammation index; SII: Systemic immune-inflammation index; ALLC: Absolute leukocyte count; ANC: Absolute neutrophil count; ALC: Absolute lymphocyte count; AMC: Absolute monocyte count; AEC: Absolute eosinophil count; RDW: Red blood cell distribution width; LDH: Lactate dehydrogenase.